CO41 Real-World Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged ≥6 Months
Abstract
Authors
O. Dabbous M. Yang M. Georgieva W. Toro N. LaMarca A. Patel A. Anderson H. Akbarnejad S.P. Reyna